Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

NCT00560417 · Completed

Last updated 2026-05-28

This clinical trial compares two types of long-acting insulin in adults with type 2 diabetes who are already taking oral diabetes medications and another injectable drug called exenatide.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 339 people

Who can join Ages 18–74 · all sexes

Timeline Started 2007-11 · est. completion 2009-12

Where 52 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT00560417 ↗

Description as written by the study sponsor.

This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes.

Treatments tested

Insulin Lispro Protamine Suspension also known as LY275585[P] Drug

Administered subcutaneously once a day at bedtime
Insulin Glargine also known as Lantus Drug

Administered subcutaneously once a day at bedtime

Main thing measured	Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF])
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00560417 ↗